首页> 美国卫生研究院文献>other >Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1 multicentre open-label ASCEND-1 trial

【2h】

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1 multicentre open-label ASCEND-1 trial

机译：ceritinib对未接受过ALK抑制剂治疗和先前接受过ALK抑制剂治疗的ALK重排非小细胞肺癌（NSCLC）患者的颅内和全身反应：第一阶段多中心开放标签ASCEND-1的最新结果试用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 other
作者
Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw;
展开▼
作者单位

展开▼
年(卷),期 -1(17),4
年度 -1
页码 452–463
总页数 25
原文格式 PDF
正文语种
中图分类
关键词
Ceritinib ALK inhibitor NSCLC Brain metastases;

机译：Ceritinib;ALK抑制剂;NSCLC;脑转移;

相似文献

外文文献
中文文献
专利

1. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial [J] . Kim Dong-Wan, Mehra Ranee, Tan Daniel S. W., The lancet oncology . 2016,第4期

机译：ceritinib在ALK重排非小细胞肺癌（ASCEND-1）患者中的活性和安全性：多中心，开放标签，1期试验的最新结果
2. Activity and safety of ceritinib in patients with ALK-rearranged non- small- cell lung cancer (ASCEND- 1): updated results from the multicentre, open-label, phase 1 trial (vol 17, pg 452, 2016) [J] . Kim D-W, Mehra R., Tan D. S. W. The lancet oncology . 2016,第5期

机译：ceritinib在ALK重排非小细胞肺癌（ASCEND-1）患者中的活性和安全性：来自多中心，开放标签的1期试验的最新结果（第17卷，第452页，2016年）
3. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2 [J] . Crino Lucio, Ahn Myung-Ju, De Marinis Filippo, Journal of Clinical Oncology . 2016,第24期

机译：Ceritinib对先前接受化学疗法和Crizotinib治疗的ALK重排非小细胞肺癌患者的全身和颅内活性的多中心II期研究：ASCEND-2的结果
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL [O] . Alice Shaw, Ranee Mehra, Daniel S.W. Tan, 2014

机译：BM-32CERITINIB（LDK378）用于治疗ASCEND-1试验中发生了ALK变种（ALK +）非小细胞肺癌（NSCLC）和脑转移瘤（BM）的患者
7. Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial [O] . Dong-Wan Kim, Ranee Mehra, Daniel S W Tan, 2016

机译：Alk -rearanged非小细胞肺癌患者Ceritinib的活性和安全性（Ascend-1）：Multicentre，Open-Label，第1阶段试验的更新结果

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1 multicentre open-label ASCEND-1 trial

著录项

引文网络

相似文献

相关主题

期刊订阅